Weill Medical College of Cornell University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Weill Medical College of Cornell University sits in the top decile of US sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count).

701 total trials 127 currently recruiting 387 completed early-phase tilt top decile by trial count

Weill Medical College of Cornell University: 701 sponsored US clinical trials, 127 recruiting.

Weill Medical College of Cornell University sponsors 701 registered US clinical trials on ClinicalTrials.gov, 127 of them currently recruiting, and 387 completed. 89 of these trials are in Phase 3-4 (later-stage) and 197 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 20 trials.

Top-decile sponsor footprint

Weill Medical College of Cornell University ranks in the top decile of sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

387 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

701 total, page 5 of 15

TERMINATED Phase 4

HCV Test and Treat Utilizing Simplified HCV Patient Education

NCT05582681

COMPLETED Phase 4

Hydrocodone Compared to Acetaminophen and Ibuprofen for Post-nail Procedure Analgesia

NCT05544734

TERMINATED Phase 4

Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical Trial

NCT05293106

COMPLETED

The Effect of Posterior Pericardiotomy on the Incidence of Atrial Fibrillation After Cardiac Surgery-Extended Follow-Up

NCT05903222

COMPLETED NA

The Effect of Simulation-based Training on Confidence and Competence in Obtaining Vitals in a Child With Autism

NCT05288868

COMPLETED NA

Leveraging Home Health Aides to Improve Outcomes in Heart Failure

NCT04239911

COMPLETED NA

The Feasibility of Engage Therapy With Video Support for Homebound Older Adults

NCT05346055

COMPLETED NA

Patient Experiences With Virtual Reality Mindfulness Skills Training

NCT05291533

TERMINATED Phase 2

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

NCT05170009

COMPLETED NA

A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors

NCT05136092

COMPLETED NA

Piloting a Multi-component Technology-based Care Intervention to Address Patient Symptoms in Home Hospice

NCT04243538

COMPLETED NA

Virtual Reality in Laryngology

NCT05218967

TERMINATED Phase 2

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

NCT04843579

TERMINATED

COVID-19 (Coronavirus Disease-2019) Psychiatric Outcomes

NCT05119400

TERMINATED Phase 2

A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors

NCT04925947

COMPLETED NA

Implementing a Family Caregiver Checklist in Primary Care: A Pilot Study

NCT04946942

TERMINATED NA

Evaluation of Ability to Detect Bowel Gas During Laparoscopic Right Colectomy With Intracorporeal Anastomosis

NCT04964297

COMPLETED NA

Positive Affect as a Source of Resilience for Adults in Chronic Pain

NCT04869345

COMPLETED NA

Glucose Testing in GDM: Adherence to One- Versus Two-hour Postprandial Glucose Monitoring in Gestational Diabetics

NCT05062460

COMPLETED Phase 2

Improving Cognitive Health in COVID-19 Survivors

NCT04843930

TERMINATED Phase 2

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

NCT04951115

COMPLETED NA

PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2

NCT04815876

COMPLETED NA

Mobile Cognitive Behavior Therapy Targeting Anxiety Disorders

NCT05130281

TERMINATED NA

A Prospective Trial on Nerve Sparing Techniques Performed in Radical Prostatectomy

NCT04393831

TERMINATED

Evaluation of a Remote Asthma Monitoring Program to Improve Health Outcomes in Pediatric Asthma

NCT05139485

COMPLETED NA

Developing and Piloting a Multi-component Technology-based Care Intervention to Address Patient Symptoms and Caregiver Burden in Home Hospice. Phase 1.

NCT04074304

COMPLETED

Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for Treatment

NCT04890314

TERMINATED Phase 2

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

NCT04685499

COMPLETED NA

Adaptation of Ca-HELP Intervention in Rural Geriatric Cancer Patient Population

NCT04262232

COMPLETED NA

The Impact of Food Order on Glycemic Excursions in Type 2 Diabetes Assessed by Continuous Glucose Monitoring

NCT04738799

COMPLETED Phase 4

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

NCT04757584

COMPLETED Phase 4

Impact of Beta-blockers on Physical Function in HFpEF

NCT04767061

COMPLETED NA

PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy

NCT04843566

COMPLETED

Comparative Effectiveness of Telemedicine in Primary Care

NCT04684836

COMPLETED Phase 4

Use of Platelet-rich Plasma (PRP) Therapy in Patients With Brittle Nail Syndrome

NCT04941807

TERMINATED Phase 2

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

NCT04631744

TERMINATED

pCHIP: Prostate Cancer Health Impact Program

NCT04293406

TERMINATED Phase 2

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

NCT04149821

COMPLETED NA

Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients

NCT04672161

COMPLETED NA

Cardiovascular Risk Assessment for Patients With Rheumatoid Arthritis Arthritis:

NCT04488497

COMPLETED Phase 2

Rimegepant in Moderate Plaque-type Psoriasis

NCT04629950

COMPLETED

COVID-19 Respiratory Outcomes Registry

NCT05074875

COMPLETED NA

The Impact of Time Restricted Feeding in Crohn's Disease

NCT04271748

TERMINATED NA

Cognitive Training in Stroke Rehabilitation

NCT04472351

TERMINATED Phase 4

Naltrexone Treatment for Prolonged Grief Disorder (PGD)

NCT04547985

COMPLETED NA

Telehealth Language Intervention for Children With Autism Ages 2-4 Years

NCT04675580

COMPLETED Phase 1

Evaluation of PSMA Antagonist Produced by Two Different Methods

NCT04685811

COMPLETED

Hypertension, Brain Clearance, and Markers of Neurodegeneration

NCT05785871

COMPLETED Phase 4

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

NCT04530630

COMPLETED NA

After Cesarean Time Interval for Exercise (ACTIVE) Trial

NCT04345757

← Previous Page 5 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 86
Phase 2 111
Phase 3 26
Phase 4 63

What is open in the Weill Medical College of Cornell University pipeline

127 recruiting of 701 indexed (18% open); 387 completed (55%).

Phase mix: 89 late (III/IV) vs 197 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Weill Medical College of Cornell University: open-pipeline peers nationwide

Peers matched on 701 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share Weill Medical College of Cornell UniversityIcahn School of Medicine at Mount SinaiSanofiThe Cleveland ClinicUniversity of MiamiChildren's Hospital of PhiladelphiaUniversity of California, BerkeleyBurke Medical Research InstituteGrand Valley State University
Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 701 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Weill Medical College of Cornell University page

701 registered trials is a research-attention snapshot, not an endorsement of Weill Medical College of Cornell University or any single study.

  • 127 of Weill Medical College of Cornell University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Weill Medical College of Cornell University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Weill Medical College of Cornell University pipeline card: 701 registered trials from official public datasets.Report a data error.